Flexion’s Slow-Release Steroid Now On Faster Track With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Following guidance from the agency on injectable osteoarthritis drug FX006, Flexion plans to file first with single-dose studies instead of waiting for longer-term data for repeated doses. This will speed up initial Phase III work by one year, the firm says.